ALZINOVA AB revenue for the last year amounted to 20.00 M SEK, the most of which — 270.00 k SEK — came from its highest performing source at the moment, Oligomer-specific Vaccine and Monoclonal Antibody, the year earlier bringing 22.29 k SEK. The greatest contribution to the revenue figure was made by Sweden — last year it brought ALZINOVA AB 270.00 k SEK, and the year before that — 22.29 k SEK.